Skip to main navigation
Skip to search
Skip to main content
Luxembourg Institute of Health Home
Search content at Luxembourg Institute of Health
Home
Profiles
Research units
Research output
Projects
Equipment
Datasets
Selegiline as immunostimulant - A novel mechanism of action?
Th Müller
, W. Kuhn
,
R. Krüger
, H. Przuntek
Research output
:
Contribution to journal
›
Article
›
Research
›
peer-review
43
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Selegiline as immunostimulant - A novel mechanism of action?'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Immunostimulant
100%
Novel Mechanism of Action
100%
Selegiline
100%
Tumor Necrosis Factor-α
66%
Interleukin-6
66%
Interleukin-1β
66%
Parkinson's Disease
33%
Alzheimer's Disease
33%
Bacterial Infection
33%
Viral Infection
33%
Peripheral Blood
33%
Alzheime's Disease
33%
Immune Response
16%
Survival Rate
16%
Lines of Evidence
16%
Neurological Deficit
16%
Chronic Inflammatory Diseases
16%
Mechanism of Action
16%
Cognitive Decline
16%
Supernatant
16%
Animal Trial
16%
Healthy Blood Donors
16%
Immune Suppressed
16%
Neuroprotective Properties
16%
ELISA Assay
16%
Human Peripheral Blood
16%
MAO-B Inhibitors
16%
Immune-mediated
16%
Cytokines/interleukins
16%
Immunology and Microbiology
Immunostimulant
100%
Tumor Necrosis Factor Alpha
100%
Interleukin 6
100%
Interleukin 1
100%
Cytokine
75%
Biosynthesis
50%
Parkinson's Disease
50%
Alzheimer's Disease
50%
Infectious Disease
25%
Viral Disease
25%
Supernatant
25%
Immune Response
25%
Survival Rate
25%
ELISA
25%
Animal Experiment
25%
Infection
25%
Neuroscience
Selegiline
100%
Immunostimulant
100%
Tumor Necrosis Factor Alpha
66%
Interleukin 6
66%
Interleukin 1
66%
Cytokine
50%
Parkinson's Disease
33%
Alzheimer's Disease
33%
Anabolism
33%
Biosynthesis
33%
ELISA
16%
Neuroprotective Agent
16%
Pharmacology, Toxicology and Pharmaceutical Science
Immunostimulant
100%
Selegiline
100%